Common polymorphisms of the peroxisome proliferator-activated receptor–γ (Pro12Ala) and peroxisome proliferator-activated receptor–γ coactivator–1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus

Hsieh, Ming‐Chia; Lin, Kun‐Der; Tien, Kai‐Jen; Tu, Shih‐Te; Hsiao, Jeng-Yueh; Chang, Shun‐Jen; Lin, Shiu‐Ru; Shing, Shih-Jang; Chen, Hung‐Chun

doi:10.1016/j.metabol.2009.10.030

Cited by 58 publications

(47 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A meta-analysis [30] reported that G allele carriers had a greater protective effect against type 2 diabetes in Asians but not in Europeans or North Americans, as well as a greater protection in lower BMI individuals. The BMIs (mean±SD) was 25.15±2.77 kg/m 2 in our study, 26.43±4.6 kg/m 2 in another Chinese population study [27] , 27.45±4.23 kg/m 2 in an Iranian population study [28] and 31.0±3.3 kg/m 2 in the Caucasian population study [29] . Subjects with lower BMI and carrying G allele of rs1801282 polymorphism showed better pioglitazone efficacy in Asians [27,28] but not in the Caucasian population with a higher BMIs [29] .…”

Section: Wwwchinapharcom Pei Q Et Alsupporting

confidence: 53%

“…The BMIs (mean±SD) was 25.15±2.77 kg/m 2 in our study, 26.43±4.6 kg/m 2 in another Chinese population study [27] , 27.45±4.23 kg/m 2 in an Iranian population study [28] and 31.0±3.3 kg/m 2 in the Caucasian population study [29] . Subjects with lower BMI and carrying G allele of rs1801282 polymorphism showed better pioglitazone efficacy in Asians [27,28] but not in the Caucasian population with a higher BMIs [29] . Therefore, the BMI difference in various ethnic groups may be one of the important ethnic factors, which influenced the effect of PPAR-γ2 rs1801282 polymorphism on pioglitazone response.…”

Section: Wwwchinapharcom Pei Q Et Alsupporting

confidence: 53%

“…We further demonstrated that it significantly affected pioglitazone response with regard to the decrease of PPG and TG levels. Another study on Chinese Han population also revealed that patients with the CG+GG genotypes of the rs1801282 polymorphism were more likely to have a positive response to pioglitazone than patients with the CC genotype [27] . Namvaran et al [28] determined that the therapeutic response of Iranian diabetic patients with the CG genotype was better than those with the CC genotype, although the difference between groups did not reach statistical significance.…”

Section: Wwwchinapharcom Pei Q Et Almentioning

confidence: 95%

See 2 more Smart Citations

PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

et al. 2012

View full text Add to dashboard Cite

Aim: To investigate the influence of peroxisome proliferator-activated receptor γ2 (PPAR-γ2) gene polymorphism rs1801282 and protein tyrosine phosphatase receptor type D (PTPRD) gene polymorphism rs17584499 on the occurrence of type 2 diabetes and pioglitazone efficacy in a Chinese Han population. Methods: One hundred ninety seven type 2 diabetes patients and 212 healthy controls were enrolled. Among them, 67 type 2 diabetes patients were administered pioglitazone (30 mg/d, po) for 3 months. All the subjects were genotyped for genetic variants in PPAR-γ2 and PTPRD using MALDI-TOF mass spectrometry. Fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, serum triglyceride, total cholesterol, low-density and high-density lipoprotein-cholesterol were determined. Results: The PPAR-γ2 gene rs1801282 polymorphism was significantly associated with type 2 diabetes susceptibility (OR=0.515, 95% CI 0.268-0.990) and the PTPRD gene rs17584499 polymorphism was also significantly associated with type 2 diabetes (OR=1.984, 95% CI 1.135-3.469) in a dominant model adjusted for age, gender and BMI. After pioglitazone treatment for 3 months, the type 2 diabetes patients with PPAR-γ2 rs1801282 CG genotypes significantly showed higher differential values of postprandial plasma glucose and serum triglyceride compared with those with rs1801282 CC genotype. The patients with PTPRD rs17584499 CT+TT genotypes showed significantly lower differential value of postprandial plasma glucose compared to those with rs17584499 CC genotype. Conclusion: Diabetes risk alleles in PPAR-γ2 (rs1801282) and PTPRD (rs17584499) are associated with pioglitazone therapeutic efficacy.

show abstract

Section: Wwwchinapharcom Pei Q Et Alsupporting

confidence: 53%

Section: Wwwchinapharcom Pei Q Et Alsupporting

confidence: 53%

Section: Wwwchinapharcom Pei Q Et Almentioning

confidence: 95%

See 1 more Smart Citation

PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

et al. 2012

View full text Add to dashboard Cite

show abstract

“…IL6 -174G>C variant was related with reduced risk of postprandial hyperglycemia but not with mRNA expression or bone markers [170]. The PPAR-Pro12Ala gene polymorphism was associated with the response to pioglitazone in Chinese patients with T2DM [171]. Pioglitazone treatment had significantly beneficial effects on serum lipid profile and blood pressure in S447S genotype carriers.…”

Section: Othersmentioning

confidence: 86%

Pharmacogenetics for T2DM and Anti-Diabetic Drugs

Huang¹,

Liu²

2011

Recent Advances in the Pathogenesis, Prevention and Management of Type 2 Diabetes and Its Complications

View full text Add to dashboard Cite

“…In 250 Chinese T2DM patients on pioglitazone (30 mg/day for 24 weeks), the Ala12Ala and Pro12Ala genotypes and Ala allele of the PPARγ gene were significantly more frequent in pioglitazone responders than in nonresponders (26.0% versus 13.5%, P =0.025 and 15.6% versus 7.3%, P =0.008) 24. The decrease in FPG (2.8 mmol/L [50.4 mg/dL] versus 2.4 mmol/L [43.3 mg/dL], P <0.001) and A 1c (0.57% versus 0.35%, P =0.004) levels was significantly greater in subjects with the Pro12Ala and Ala12Ala carriers than in Pro12Pro carriers.…”

Section: Thiazolidinedionesmentioning

confidence: 99%

Patient profiling in diabetes and role of canagliflozin

Amblee

2014

PGPM

View full text Add to dashboard Cite

Genome-wide association studies have opened the door for patient profiling and research into genetic variants in multifactorial T2DM. Clinically, it may be possible to tailor the type of medication used based on the presence or absence of the various genetic variants. However, the polymorphisms studied may only explain some of the variability in response to T2DM drugs and needs further validation to ensure its authenticity. There are still unidentified factors which appear to play a role in the interindividual variability seen in clinical practice. The potential exists for pharmacogenomics to promote efficacious, safe, and cost-effective individualized diabetes management. Pharmacogenomics is still in its early stages, and the idea of defining patients genetically to predict individual responses to drugs and obtain safe and effective T2DM management is promising, in spite of existing barriers. Currently, clinical profiling of patients with T2DM and using an individualized approach with most drugs, including canagliflozin, based on comorbid conditions still remains the most accepted approach for the management of T2DM.

show abstract

Common polymorphisms of the peroxisome proliferator-activated receptor–γ (Pro12Ala) and peroxisome proliferator-activated receptor–γ coactivator–1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus

Cited by 58 publications

References 30 publications

PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

PPAR-γ2 and PTPRD gene polymorphisms influence type 2 diabetes patients' response to pioglitazone in China

Pharmacogenetics for T2DM and Anti-Diabetic Drugs

Patient profiling in diabetes and role of canagliflozin

Contact Info

Product

Resources

About